SecBot SecBot
PRESS-RELEASE ·Filed Jul 15, 2026

AXSM

Axsome Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The NDA acceptance and absence of an AdCom are modest positives that de-risk the regulatory path, but the PDUFA date is nearly 10 months out. Traders should monitor for any FDA review updates or clinical data releases ahead of May 2027. The stock's historical neutral filings have underperformed, so near-term upside may be limited until a clearer catalyst emerges.

DirectionBullish
Confidencehigh
Horizonmonths

AXS-12

● Neutral Named in this press release
Impact
Phase
Filed/PDUFA (NDA accepted; Phase 3 completed)
Time to market
NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
Next catalyst
PDUFA date · May 1, 2027 165d

What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$237.53
T+0 close · Jul 15, 2026 · via day close
Latest settled
−28.40%
T+60 · $170.08
Vs SPY
−30.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $237.53entry
  2. T+1 · 4mo ago −0.21%α +0.34% · $237.04
  3. T+5 · 4mo ago +0.88%α +1.86% · $239.62
  4. T+20 · 3mo ago −9.63%α −11.97% · $214.66
  5. T+60 · 6w ago −28.40%α −30.93% · $170.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting, which reduces regulatory uncertainty. This is a procedural milestone for a mid-stage pipeline asset, not a revenue-generating event, and the stock's historical reaction to neutral filings has been negative on average.

Key Facts

  • FDA accepted NDA filing for AXS-12 (reboxetine) to treat cataplexy in narcolepsy
  • PDUFA target action date set for May 1, 2027
  • FDA indicated no advisory committee meeting is currently planned
  • AXS-12 has Orphan Drug Designation for narcolepsy
  • Cataplexy affects an estimated 70% of narcolepsy patients

Financial Impact

No financial terms disclosed; AXS-12 is not yet approved and has no revenue. Orphan drug designation provides market exclusivity potential if approved.

pipeline valueregulatory risk

Risk Factors

  • FDA may still issue a Complete Response Letter (CRL) at the PDUFA date
  • AXS-12 is not yet approved and has no commercial revenue
  • Long timeline to PDUFA (May 2027) leaves room for negative developments

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3327580

Track record

26 reports on AXSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Viewing Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026